Publications by authors named "Blandine Roux"
Article Synopsis
- Cancer cells adapt to stress, creating weaknesses that can be targeted; a study found that VCP, a stress-related protein, is particularly vulnerable in acute myeloid leukemia (AML).
- The research showed that AML is the most sensitive cancer type to VCP inhibition, validated through various models and techniques.
- A new VCP inhibitor, CB-5339, was developed and shown to effectively work with DNA-damaging drugs like anthracyclines, supporting its potential for clinical testing in AML treatment.
Over the past decades, genetic advances have allowed a more precise molecular characterization of AML with the identification of novel oncogenes and tumor suppressors as part of a comprehensive AML molecular landscape. Recent advances in genetic sequencing tools also enabled a better understanding of AML leukemogenesis from the preleukemic state to posttherapy relapse. These advances resulted in direct clinical implications with the definition of molecular prognosis classifications, the development of treatment recommendations based on minimal residual disease (MRD) measurement and the discovery of novel targeted therapies, ultimately improving AML patients' overall survival.
View Article and Find Full Text PDFPhagocytes, especially neutrophils, can produce reactive oxygen species (ROS), through the activation of the NADPH oxidase (NOX2). Although this enzyme is crucial for host-pathogen defense, ROS production by neutrophils can be harmful in several pathologies such as cardiovascular diseases or chronic pulmonary diseases. The ROS production by NOX2 involves the assembly of the cytosolic subunits (p67, p47, and p40) and Rac with the membrane subunits (gp91 and p22).
View Article and Find Full Text PDF